Delivery Order SPE2DB20D1047-SPE2DB25FF55L
Award Date 4/21/25
Potential Completion Date 4/22/25
Potential Value $1.3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,908.64 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on September 4, 2025, with completion scheduled for September 5, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a delivery order valued at $1,466.05 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and diabetes treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $11,438.70 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pens on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used in diabetes and weight management treatment, reflecting DLA's...
- The Defense Logistics Agency awarded a delivery order valued at $11,216.68 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on September 4, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the Defense Health System's...
- The Defense Logistics Agency awarded a delivery order valued at $9,727.53 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 12, 2025, with completion due by August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $10,676.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on July 11, 2025, with an ultimate completion date of July 14, 2025. This firm fixed price delivery order is being performed at the contractor's facility in Conshohocken, Pennsylvania and carries no set-aside designation, indicating it was competitively awarded. Zepbound is a GLP-1 receptor agonist pharmaceutical used for weight management...
- The Defense Logistics Agency awarded a delivery order valued at $8,304.30 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pen injections on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order valued at $30,536.46 to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injections on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist used in diabetes and weight management treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $11,574.72 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on April 24, 2025, with an ultimate completion date of April 25, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. The...